Now that Biogen’s aducanumab team and the FDA’s Billy Dunn have been battered by a gamut of angry experts, the analysts are weighing in
On Friday afternoon, some angry and deeply disturbed experts on the FDA advisory panel slapped down Biogen $BIIB and the FDA’s Billy Dunn in a way that’s never been seen before during an adcomm meeting. Then the analysts’ autopsies started to arrive, dissecting how a drive to gain experts’ support for the Alzheimer’s drug aducanumab turned into a bloody rout, with a near-unanimous vote at the end mauling the FDA’s position on efficacy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.